Professional Summary
Professional Overview
Allen Horhota is an experienced biopharmaceutical executive with a strong background in RNA sciences and drug delivery. As the Vice President of RNA Sciences at Orna Therapeutics, he leads a team of scientists and researchers focused on advancing innovative RNA-based therapeutics.
Experience Summary
Current Role
As the Vice President of RNA Sciences at Orna Therapeutics, Allen is responsible for overseeing the company's research and development efforts in the field of RNA-based medicines. He manages a team of researchers and scientists, guiding the development of novel RNA delivery technologies and the translation of these innovations into potential therapeutic candidates. Under his leadership, Orna Therapeutics has made significant strides in expanding its RNA science capabilities and advancing its pipeline of RNA-based therapies.
Career Progression
Prior to his current role, Allen held several leadership positions in the biopharmaceutical industry, including Senior Director and Head of Delivery at Orna Therapeutics, Associate Director at Moderna Therapeutics and BIND Therapeutics. In these roles, he demonstrated his expertise in drug delivery, process sciences, and the development of cutting-edge therapeutic platforms. His experience spans both early-stage research and the successful translation of promising technologies into clinical-stage programs.
Academic Background
Allen holds a Ph.D. in Chemistry from Boston College, where he conducted research focused on the development of novel drug delivery systems. His postdoctoral work at The Scripps Research Institute further expanded his expertise in the field of RNA sciences and therapeutics.
Areas of Expertise
- RNA-based drug delivery and formulation
- Innovative therapeutic platform development
- Translational research and the advancement of novel therapies
- Building and leading high-performing research and development teams
- Collaboration with academic and industry partners to drive scientific innovation
Professional Impact
Throughout his career, Allen has made significant contributions to the advancement of RNA-based therapeutics. He has been instrumental in the development of Orna Therapeutics' proprietary RNA delivery technologies, which have the potential to unlock new frontiers in the field of RNA-based medicine. Allen's expertise and leadership have been pivotal in the company's progress, and his work has the potential to positively impact the lives of patients suffering from a wide range of diseases.
Conclusion
With his deep expertise in RNA sciences, proven track record of advancing innovative therapeutic platforms, and exceptional leadership skills, Allen Horhota is well-positioned to continue driving the development of transformative RNA-based therapies at Orna Therapeutics. His commitment to scientific excellence and his passion for translating cutting-edge research into real-world solutions make him a valuable asset to the biopharmaceutical industry.
